OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DOL.PSX60

Descon Oxychem Ltd

Commodity ChemicalsVerified

Descon Oxychem has a strong liquidity position, with a current ratio of 2.28, indicating that it holds more than twice as much in current assets as it does in current liabilities. However, the company has a negative net cash position after subtracting total debt, which raises some liquidity concerns. The company's debt-to-equity ratio is 0.06, suggesting a relatively low reliance on debt financing and a strong equity base. In terms of profitability, Descon Oxychem demonstrates a return on equity (ROE) of 25.48% and a return on assets (ROA) of 18.37%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the typical thresholds for the Commodity Chemicals industry, suggesting that the company is outperforming its peers in terms of profitability. The company's revenue is derived from a diverse set of products and industries, including the textile, paper and pulp, food packaging, mining, cosmetics, and poultry sectors. This diversification helps to mitigate the risk of over-reliance on any single market. However, the exact revenue concentration by segment or geography is not disclosed in the available data. Looking at the growth trajectory, the company's capital expenditure is negative at -518.88 million PKR, indicating that it is not investing in new capital assets at the moment. This could suggest a period of maintenance or a strategic decision to focus on operational efficiency rather than expansion. The company's free cash flow is relatively low at 32.12 million PKR, which may limit its ability to reinvest in growth opportunities. The risk assessment for Descon Oxychem indicates a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after subtracting total debt. The dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term. Recent events and filings do not show any significant changes in the company's operations or financial strategy. The company's analyst estimates suggest a neutral outlook, with one "hold" recommendation and no strong buy or sell recommendations. This indicates that analysts are neither particularly bullish nor bearish on the company's prospects in the near term.

30-day price · DOL.PSX+5.30 (+19.7%)
Low$25.36High$33.20Close$32.23As of15 May, 00:00 UTC
Profile
CompanyDescon Oxychem Ltd
TickerDOL.PSX
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Descon Oxychem Limited is engaged in the manufacture, procurement, and sale of hydrogen peroxide and allied products, including Textox, Printox, Aseptox, Sanidol, Dolox, Cosmox, and Careox, which serve the textile, paper and pulp, food packaging, mining, cosmetics, and poultry industries.

Classification. Descon Oxychem is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a confidence level of 0.92.

Descon Oxychem has a strong liquidity position, with a current ratio of 2.28, indicating that it holds more than twice as much in current assets as it does in current liabilities. However, the company has a negative net cash position after subtracting total debt, which raises some liquidity concerns. The company's debt-to-equity ratio is 0.06, suggesting a relatively low reliance on debt financing and a strong equity base. In terms of profitability, Descon Oxychem demonstrates a return on equity (ROE) of 25.48% and a return on assets (ROA) of 18.37%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the typical thresholds for the Commodity Chemicals industry, suggesting that the company is outperforming its peers in terms of profitability. The company's revenue is derived from a diverse set of products and industries, including the textile, paper and pulp, food packaging, mining, cosmetics, and poultry sectors. This diversification helps to mitigate the risk of over-reliance on any single market. However, the exact revenue concentration by segment or geography is not disclosed in the available data. Looking at the growth trajectory, the company's capital expenditure is negative at -518.88 million PKR, indicating that it is not investing in new capital assets at the moment. This could suggest a period of maintenance or a strategic decision to focus on operational efficiency rather than expansion. The company's free cash flow is relatively low at 32.12 million PKR, which may limit its ability to reinvest in growth opportunities. The risk assessment for Descon Oxychem indicates a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after subtracting total debt. The dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term. Recent events and filings do not show any significant changes in the company's operations or financial strategy. The company's analyst estimates suggest a neutral outlook, with one "hold" recommendation and no strong buy or sell recommendations. This indicates that analysts are neither particularly bullish nor bearish on the company's prospects in the near term.
Key takeaways
  • Descon Oxychem has a strong ROE of 25.48% and ROA of 18.37%, indicating efficient use of equity and assets.
  • The company's liquidity position is strong with a current ratio of 2.28, but it has a negative net cash position after subtracting total debt.
  • The company's debt-to-equity ratio is 0.06, suggesting a low reliance on debt financing.
  • The company's capital expenditure is negative, indicating no new capital investments at the moment.
  • Analysts have a neutral outlook on the company, with one "hold" recommendation and no strong buy or sell recommendations.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue$6.00B
Gross profit$1.78B
Operating income$1.32B
Net income$860.2M
R&D
SG&A
D&A
SBC
Operating cash flow$1.56B
CapEx-$518.9M
Free cash flow$32.1M
Total assets$4.68B
Total liabilities$1.31B
Total equity$3.38B
Cash & equivalents
Long-term debt$207.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.38B
Net cash-$207.3M
Current ratio2.3
Debt/Equity0.1
ROA18.4%
ROE25.5%
Cash conversion1.8%
CapEx/Revenue-8.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
MetricDOL.PSXActivity
Op margin22.0%0.4% medp25 -8.0% · p75 16.0%top quartile
Net margin14.3%2.3% medp25 -11.6% · p75 11.8%top quartile
Gross margin29.7%20.8% medp25 14.9% · p75 24.0%top quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-8.6%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity6.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Observations
IR observations
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 07:18 UTC#85b1ff5a
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 07:20 UTCJob: 5de3813d